




PHARMACEUTICAL 2021

Calithera Biosciences Inc.
Rank 183 of 402





PHARMACEUTICAL 2021

Calithera Biosciences Inc.
Rank 183 of 402



The relative strengths and weaknesses of Calithera Biosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Calithera Biosciences Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 65% points. The greatest weakness of Calithera Biosciences Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 58% points.

The company's Economic Capital Ratio, given in the ranking table, is 115%, being 68% points above the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	118,703
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	18,401
Liabilities, Non-Current	4,815
Other Assets	6,194
Other Compr. Net Income	-39
Other Expenses	0
Other Liabilities	0
Other Net Income	0
Other Revenues	1,250
Property and Equipment	690
Research and Development	71,015
Selling, General and Administrative Expense	20,372

Output Variable	Value in 1000 USD
Assets	125,587
Liabilities	23,216
Expenses	91,387
Revenues	1,250
Stockholders Equity	102,371
Net Income	-90,137
Comprehensive Net Income	-90,156
Economic Capital Ratio	115%